CURRENT REPORT 37/2023
July 31, 2023

Conclusion of the agreement in the area of securing venetoclax supply chain for RVU120 Phase II clinical trial in combination therapy in hematology

The Management Board of Ryvu Therapeutics S.A. with its registered office in Krakow, Poland ("Company", "Ryvu"), announces that on July 31, 2023, an agreement was concluded with Clinical Services International Limited with its registered office in London, UK (“CSI”), in the area of securing venetoclax supply chain for the RIVER-81 study (“Agreement”). The conclusion of the Agreement serves the implementation of the goals indicated in the "Development Plans for 2022-2024" ("Development Plans"), as announced by the Company in the current report 16/2022 on August 19, 2022.

The subject of the Agreement is to provide supply chain-related services, including management, procurement, storage, delivery, labelling, QP release, status monitoring, returns, as well as utilization of venetoclax in the RIVER-81 clinical study.

The total value of the Agreement with CSI will amount up to approx. EUR 3.94 million.

The costs associated with the implementation of the Agreement will be co-financed by the Medical Research Agency ("ABM") from the state budget, in the framework of a competition for the development of targeted or personalized medicine based on nucleic acid therapy or small molecule compounds, in which the Company has been selected as one of the beneficiaries as informed in the current report no. 29/2023 on June 13, 2023, provided that an agreement is signed with ABM.

The aim of the RIVER-81 study (“Study”), a Phase II, multicenter, open-label clinical trial, is to evaluate the safety and efficacy of RVU120 in combination with venetoclax in patients with relapsed/refractory Acute Myeloid Leukemia (AML), who have failed prior therapy with venetoclax and a hypomethylating agent. The initiation of this study is planned for the second half of 2023.

Clinical Services International (CSI) is a global company, providing sourcing and management of quality certified commercially available medicines (comparators, concomitant medication, rescue medication) for clinical trials.

The Agreement meets the criteria of a significant agreement due to its importance for the further clinical development of the RVU120 program and constitutes an element of the Development Plans implementation.

Disclaimer: This English language translation has been prepared solely for the convenience of English-speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions,

the Polish version shall prevail. Ryvu Therapeutics S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: 17.1 MAR

Representatives of the Issuer:

- Paweł Przewięźlikowski – President of the Management Board
- Kamil Sitarz – Member of the Management Board